Praxis Precision Medicines (PRAX) EV/FCF: History & Chart

Praxis Precision Medicines, Inc.(PRAX)

Biotechnology · Boston, MA

$275.87-7.69 (-2.71%)

Delayed quote: Oct 6, 2026, 1:55 PM EDT

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Boston, MA

168 employees

www.praxismedicines.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marcio Silva De'Souza

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Praxis Precision Medicines, Inc. (PRAX)	$7.68B	N/A	N/A	N/A	N/A
Cytokinetics, Incorporated (CYTK)vs ›	$7.62B	N/A	31.54x	39.90x	39.90x
HealthEquity, Inc. (HQY)vs ›	$7.61B	17.66x	21.78x	38.63x	187.17x
Hinge Health, Inc. (HNGE)vs ›	$7.56B	25.35x	25.74x	30.03x	30.03x
Caris Life Sciences, Inc. (CAI)vs ›	$7.93B	52.49x	52.04x	52.04x	52.04x
TG Therapeutics, Inc. (TGTX)vs ›	$7.97B	474.33x	504.35x	196.05x	196.05x
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.32B	N/A	178.07x	109.13x	82.68x
Oscar Health, Inc. (OSCR)vs ›	$8.36B	1.09x	2.20x	3.82x	3.92x
Alkermes plc (ALKS)vs ›	$7.00B	36.39x	22.08x	16.34x	41.62x
Kymera Therapeutics, Inc. (KYMR)vs ›	$8.58B	N/A	34.26x	34.16x	34.16x

NAME

MARKET CAP

EV/FCF RATIO

TTM

Praxis Precision Medicines, Inc. (PRAX)

$7.68B

N/A

Cytokinetics, Incorporated (CYTK)vs ›

$7.62B

N/A

31.54x

39.90x